CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Symptoms questionnareWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug19 40ml blood sample Wiki 1.00
drug152 COVID-19 Serology Wiki 0.71
drug151 COVID-19 RT-PCR Wiki 0.58

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001168 Arthritis NIH 0.58

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluation of the Immune Response in Symptomatic and Asymptomatic Patients' Diagnosed Witih COVID-19

The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.

NCT04348422 COVID-19 Diagnostic Test: COVID-19 RT-PCR Diagnostic Test: COVID-19 Serology Other: Symptoms questionnare

Primary Outcomes

Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection

Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA)

Time: 100 days

Description: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection

Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)

Time: 100 days

Secondary Outcomes

Description: the mean time patients devleoped IgM

Measure: Time to IgM

Time: Evaluated within a 100 days followup

Description: the mean time patients devleoped IgG

Measure: Time to IgG

Time: Evaluated within a 100 days followup

Description: the mean time patients devleoped IgG

Measure: Time to IgA

Time: Evaluated within a 100 days followup

Description: Cohen's kappa coefficient calculated between the different serology kits used for evaluation

Measure: Serology kits inter-observer agreement

Time: Evaluated within a 100 days followup


No related HPO nodes (Using clinical trials)